Startseite Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome

  • Jun Qian , Xing-xing Chen , Wei Qian EMAIL logo , Jing Yang , Xiang-mei Wen , Ji-chun Ma , Zhao-qun Deng , Zhen Qian , Ying-ying Zhang und Jiang Lin EMAIL logo
Veröffentlicht/Copyright: 12. August 2014
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 52 Heft 12

Abstract

Background:CTNNA1 gene is a putative tumor suppressor for its roles in inhibiting proliferation and promoting apoptosis. Aberrant expression of CTNNA1 is regulated by epigenetic mechanisms including both promoter methylation and histone deacetylation in hematopoietic malignancies. However, the clinical relevance of CTNNA1 methylation remains rarely known in myelodysplastic syndrome (MDS).

Methods: We investigated the methylation status of CTNNA1 promoter using methylation-specific PCR (MSP) and analyzed its clinical significance in Chinese MDS patients.

Results: Aberrant hypermethylation of CTNNA1 gene was identified in 22% (18/83) of the patients. CTNNA1 expression was significantly correlated with promoter methylation status (p<0.05). No significant differences were observed in the age, sex, and blood parameters between patients with and without CTNNA1 hypermethylation (p>0.05). The frequency of CTNNA1 hypermethylation was significantly higher in patients with isolated del(5q) (3/4, 75%) than those with other abnormal karyotypes (4/23, 17%) and also than those with normal karyotypes (11/54, 20%) (p=0.042 and 0.040, respectively). The patients with higher IPSS risks (Int-2/High) had significantly increased incidence of CTNNA1 methylation than those with lower risks (Low/Int-1) (36% vs. 15%, p=0.049). Although the estimated 50% survival time of the CTNNA1-methylated group [median 13 months, 95% confidence interval (CI) 3–22 months] was shorter than that of CTNNA1-unmethylated group (median 24 months, 95% CI 7–41 months), the difference was not statistically significant (p=0.330).

Conclusions: Our data confirm that aberrant CTNNA1 methylation is a common event and is associated with higher IPSS risk in MDS.

Keywords: CTNNA1; methylation; myelodysplastic syndrome
Corresponding authors: Jiang Lin, Laboratory Center, Affiliated People’s Hospital of Jiangsu University, 8 Dianli Road, 212002 Zhenjiang, P.R. China, Phone: +86 511 88915586, Fax: +86 511 85234387, E-mail: ; and Wei Qian, Laboratory Center, Affiliated People’s Hospital of Jiangsu University, 8 Dianli Road, 212002 Zhenjiang, P.R. China, Phone: +86 511 88917833, Fax: +86 511 85234387, E-mail:

Acknowledgments

This study was supported by National Natural Science Foundation of China (81270630, 81172592), Science and Technology Special Project in Clinical Medicine of Jiangsu Province (BL2012056), 333 Project of Jiangsu Province (BRA2011085, BRA2013136), Science and Technology Infrastructure Program of Zhenjiang (SS2012003), Social Development Foundation of Zhenjiang (SH2013042, SH2013082), the Innovation Project of Graduate Student in Jiangsu Province’s Ordinary University (CXLX12_0673), and Jiangsu Government Scholarship for Overseas Studies.

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research funding played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

References

1. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC, 2008.Suche in Google Scholar

2. Itzykson R, Fenaux P. Epigenetics of myelodysplastic syndromes. Leukemia 2014;28:497–506.10.1038/leu.2013.343Suche in Google Scholar PubMed

3. Issa JP. The myelodysplastic syndrome as a prototypical epigenetic disease. Blood 2013;121:3811–7.10.1182/blood-2013-02-451757Suche in Google Scholar PubMed PubMed Central

4. Estey EH. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia 2013;27:1803–12.10.1038/leu.2013.173Suche in Google Scholar PubMed

5. Santini V, Melnick A, Maciejewski JP, Duprez E, Nervi C, Cocco L, et al. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Crit Rev Oncol Hematol 2013;88:231–45.10.1016/j.critrevonc.2013.06.004Suche in Google Scholar PubMed

6. Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer 2002;34:255–68.10.1002/gcc.10083Suche in Google Scholar PubMed

7. Van Aken E, De Wever O, Correia da Rocha AS, Mareel M. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch 2001;439:725–51.10.1007/s004280100516Suche in Google Scholar PubMed

8. Liu TX, Becker MW, Jelinek J. Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007;13:78–83.10.1038/nm1512Suche in Google Scholar PubMed

9. Piao HL, Yuan Y, Wang M, Sun Y, Liang H, Ma L. α-catenin acts as a tumour suppressor in E-cadherin-negative basal-like breast cancer by inhibiting NF-κB signalling. Nat Cell Biol 2014;16:245–54.10.1038/ncb2909Suche in Google Scholar PubMed PubMed Central

10. Ye Y, McDevitt MA, Guo M, Zhang W, Galm O, Gore SD, et al. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res 2009;69:8482–90.10.1158/0008-5472.CAN-09-1153Suche in Google Scholar PubMed PubMed Central

11. Fu CT, Zhu KY, Mi JQ, Liu YF, Murray ST, Fu YF, et al. An evolutionarily conserved PTEN-C/EBPa-CTNNA1 axis controls myeloid development and transformation. Blood 2010;115:4715–24.10.1182/blood-2009-11-255778Suche in Google Scholar PubMed

12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–99.10.1111/j.1365-2141.1982.tb08475.xSuche in Google Scholar

13. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–88 [Erratum in: Blood 1998;91:1100].10.1182/blood.V89.6.2079Suche in Google Scholar

14. Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, et al. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One 2011;6:e26906.10.1371/journal.pone.0026906Suche in Google Scholar PubMed PubMed Central

15. Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 2012;91:519–25.10.1007/s00277-011-1352-7Suche in Google Scholar PubMed

16. Qian J, Yao DM, Lin J, Qian W, Wang CZ, Chai HY, et al. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One 2012;7:e45760.10.1371/journal.pone.0045760Suche in Google Scholar PubMed PubMed Central

17. Yang J, Qian J, Lin J, Yang XF, Qian W, Chen Q, et al. Development of a high-resolution melting analysis for the detection of the SF3B1 mutations. Genet Test Mol Biomarkers 2013;17:342–7.10.1089/gtmb.2012.0364Suche in Google Scholar PubMed

18. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994;84:3253–60.10.1182/blood.V84.10.3253.3253Suche in Google Scholar

19. Horrigan SK, Arbieva ZH, Xie HY, Kravarusic J, Fulton NC, Naik H, et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood 2000;95:2372–7.10.1182/blood.V95.7.2372Suche in Google Scholar

20. Eisenmann KM, Dykema KJ, Matheson SF, Kent NF, DeWard AD, West RA, et al. 5q-myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics. Oncogene 2009;28:3429–41.10.1038/onc.2009.207Suche in Google Scholar PubMed

21. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava EM, Kosma VM. Reduced expression of alpha catenin is associated with poor prognosis in colorectal carcinoma. J Clin Pathol 1999;52:10–6.10.1136/jcp.52.1.10Suche in Google Scholar PubMed PubMed Central

22. Böhm J, Niskanen L, Kiraly K, Kellokoski J, Eskelinen M, Hollmen S, et al. Expression and prognostic value of alpha-, beta-, and gamma-catenins indifferentiated thyroid carcinoma. J Clin Endocrinol Metab 2000;85:4806–11.Suche in Google Scholar

23. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, Giannopoulou I, Keramopoulos A, Davaris P, et al. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology 2002;40:536–46.10.1046/j.1365-2559.2002.01392.xSuche in Google Scholar

24. Saito T, Oda Y, Sakamoto A, Tamiya S, Kinukawa N, Hayashi K, et al. Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma. J Pathol 2000;192:342–50.10.1002/1096-9896(2000)9999:9999<::AID-PATH705>3.0.CO;2-RSuche in Google Scholar

25. Van Oort IM, Tomita K, van Bokhoven A, Bussemakers MJ, Kiemeney LA, Karthaus HF, et al. The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. Prostate 2007;67:1432–8.10.1002/pros.20626Suche in Google Scholar

26. Aaltomaa S, Lipponen P, Kärjä V, Lundstedt S, Lappi J, Kosma VM. The expression and prognostic value of alpha-, beta- and gamma-catenins in renal cell carcinoma. Anticancer Res 2004;24:2407–13.Suche in Google Scholar

27. Lee YC, Wu CT, Chen CS, Hsu HH, Chang YL. The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size. J Thorac Cardiovasc Surg 2002;123:502–7.10.1067/mtc.2002.119334Suche in Google Scholar

28. Endo K, Ueda T, Ueyama J, Ohta T, Terada T. Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients’ survival. Hum Pathol 2000;31:558–65.10.1053/hp.2000.6683Suche in Google Scholar

29. Kashibuchi K, Tomita K, Schalken JA, Kume H, Takeuchi T, Kitamura T. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. Int J Urol 2007;14:789–94.10.1111/j.1442-2042.2007.01830.xSuche in Google Scholar

30. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells. Cancer Res 1993;53: 3585–90.Suche in Google Scholar

31. Griffiths EA, Gore SD, Hooker CM, Mohammad HP, McDevitt MA, Smith BD, et al. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics 2010;5:590–600.10.4161/epi.5.7.12558Suche in Google Scholar

32. Desmond JC, Raynaud S, Tung E, Hofmann WK, Haferlach T, Koeffler HP. Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia 2007;21:1026–34.10.1038/sj.leu.2404611Suche in Google Scholar

33. Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, et al. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res 1995;55:4813–7.Suche in Google Scholar

34. Bullions LC, Notterman DA, Chung LS, Levine AJ. Expression of wildtype a-catenin protein in cells with a mutant a-catenin gene restores both growth regulation and tumor suppressor activities. Mol Cell Biol 1997;17:4501–8.10.1128/MCB.17.8.4501Suche in Google Scholar

Received: 2014-4-24
Accepted: 2014-6-16
Published Online: 2014-8-12
Published in Print: 2014-12-1

©2014 by De Gruyter

Artikel in diesem Heft

  1. Frontmatter
  2. Editorials
  3. CCLM Award for The Most Cited Paper Recently Published
  4. Laboratory preparedness to face infectious outbreaks. Ebola and beyond
  5. Reviews
  6. Determination of reference limits: statistical concepts and tools for sample size calculation
  7. Recent advances in physiological lipoprotein metabolism
  8. New laboratory markers for the management of rheumatoid arthritis patients
  9. General Clinical Chemistry and Laboratory Medicine
  10. The impact of repeat-testing of common chemistry analytes at critical concentrations
  11. Performance of CKD-EPI equation to estimate glomerular filtration rate as compared to MDRD equation in South Brazilian individuals in each stage of renal function
  12. The serum uromodulin level is associated with kidney function
  13. Efficient assessment of peripheral blood lymphocytosis in adults: developing new thresholds for blood smear review by pathologists
  14. Performance evaluation of Sysmex XN hematology analyzer in umbilical cord blood: a comparison study with Sysmex XE-2100
  15. UF-1000i: validation of the body fluid mode for counting cells in body fluids
  16. Newborn screening for haemoglobinopathies by high performance liquid chromatography (HPLC): diagnostic utility of different approaches in resource-poor settings
  17. Progressive chromogenic anti-factor Xa assay and its use in the classification of antithrombin deficiencies
  18. Reference Values and Biological Variations
  19. Thyroid-stimulating hormone reference range and factors affecting it in a nationwide random sample
  20. Reference ranges for serum β-trace protein in neonates and children younger than 1 year of age
  21. A multicenter nationwide reference intervals study for common biochemical analytes in Turkey using Abbott analyzers
  22. Serum reference intervals of homoarginine, ADMA, and SDMA in the Study of Health in Pomerania
  23. Cancer Diagnostics
  24. Low SOX17 expression: prognostic significance in de novo acute myeloid leukemia with normal cytogenetics
  25. Results of first proficiency test for KRAS testing with formalin-fixed, paraffin-embedded cell lines in China
  26. Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome
  27. Cardiovascular Diseases
  28. Association between SNP rs13376333 and rs1131820 in the KCNN3 gene and atrial fibrillation in the Chinese Han population
  29. Acknowledgment
  30. Acknowledgment
  31. Letters to the Editor
  32. Interference in thyroid hormones with Roche immunoassays: an unfinished story
  33. Discrepant results in plasma, but not serum in the Beckman Coulter DxI Access HYPERsensitive hTSH 3rd generation assay affect the management of differentiated thyroid cancer and hyperthyroid patients
  34. Improper serum separation on gel tubes: a trivial laboratory problem or an indicator of monoclonal gammopathy?
  35. Analytical comparison of the new point-of-care troponin T immunoassay on AQT90Flex® analyzer (Radiometer) and the high-sensitivity troponin T immunoassay on ModularE170® (Roche Diagnostics)
  36. Performance characteristics of the enzymatic Abbott Architect HbA1c whole blood assay
  37. Multi-center proficiency tests for Lab-MELD score diagnostics to improve the quality and safety for patients awaiting liver transplantation
  38. The apolipoprotein B/apolipoprotein A-I ratio in healthy men with normolipidemia: limits of variation and relationship with other lipid parameters
  39. Validity and reliability of the 13C-methionine breath test for the detection of moderate hyperhomocysteinemia in Mexican adults; statistical issues in validity and reliability analysis
  40. Enzymatic and endpoint methods yield comparable adenosine deaminase activity in pleural fluid samples
  41. Congress Abstract
  42. 5th Italian GREAT Network Congress
  43. Congress of Laboratory Medicine and Clinical Chemistry
https://doi.org/10.1515/cclm-2014-0446
Schlagwörter für diesen Artikel
CTNNA1; methylation; myelodysplastic syndrome

Artikel in diesem Heft

  1. Frontmatter
  2. Editorials
  3. CCLM Award for The Most Cited Paper Recently Published
  4. Laboratory preparedness to face infectious outbreaks. Ebola and beyond
  5. Reviews
  6. Determination of reference limits: statistical concepts and tools for sample size calculation
  7. Recent advances in physiological lipoprotein metabolism
  8. New laboratory markers for the management of rheumatoid arthritis patients
  9. General Clinical Chemistry and Laboratory Medicine
  10. The impact of repeat-testing of common chemistry analytes at critical concentrations
  11. Performance of CKD-EPI equation to estimate glomerular filtration rate as compared to MDRD equation in South Brazilian individuals in each stage of renal function
  12. The serum uromodulin level is associated with kidney function
  13. Efficient assessment of peripheral blood lymphocytosis in adults: developing new thresholds for blood smear review by pathologists
  14. Performance evaluation of Sysmex XN hematology analyzer in umbilical cord blood: a comparison study with Sysmex XE-2100
  15. UF-1000i: validation of the body fluid mode for counting cells in body fluids
  16. Newborn screening for haemoglobinopathies by high performance liquid chromatography (HPLC): diagnostic utility of different approaches in resource-poor settings
  17. Progressive chromogenic anti-factor Xa assay and its use in the classification of antithrombin deficiencies
  18. Reference Values and Biological Variations
  19. Thyroid-stimulating hormone reference range and factors affecting it in a nationwide random sample
  20. Reference ranges for serum β-trace protein in neonates and children younger than 1 year of age
  21. A multicenter nationwide reference intervals study for common biochemical analytes in Turkey using Abbott analyzers
  22. Serum reference intervals of homoarginine, ADMA, and SDMA in the Study of Health in Pomerania
  23. Cancer Diagnostics
  24. Low SOX17 expression: prognostic significance in de novo acute myeloid leukemia with normal cytogenetics
  25. Results of first proficiency test for KRAS testing with formalin-fixed, paraffin-embedded cell lines in China
  26. Aberrant hypermethylation of CTNNA1 gene is associated with higher IPSS risk in patients with myelodysplastic syndrome
  27. Cardiovascular Diseases
  28. Association between SNP rs13376333 and rs1131820 in the KCNN3 gene and atrial fibrillation in the Chinese Han population
  29. Acknowledgment
  30. Acknowledgment
  31. Letters to the Editor
  32. Interference in thyroid hormones with Roche immunoassays: an unfinished story
  33. Discrepant results in plasma, but not serum in the Beckman Coulter DxI Access HYPERsensitive hTSH 3rd generation assay affect the management of differentiated thyroid cancer and hyperthyroid patients
  34. Improper serum separation on gel tubes: a trivial laboratory problem or an indicator of monoclonal gammopathy?
  35. Analytical comparison of the new point-of-care troponin T immunoassay on AQT90Flex® analyzer (Radiometer) and the high-sensitivity troponin T immunoassay on ModularE170® (Roche Diagnostics)
  36. Performance characteristics of the enzymatic Abbott Architect HbA1c whole blood assay
  37. Multi-center proficiency tests for Lab-MELD score diagnostics to improve the quality and safety for patients awaiting liver transplantation
  38. The apolipoprotein B/apolipoprotein A-I ratio in healthy men with normolipidemia: limits of variation and relationship with other lipid parameters
  39. Validity and reliability of the 13C-methionine breath test for the detection of moderate hyperhomocysteinemia in Mexican adults; statistical issues in validity and reliability analysis
  40. Enzymatic and endpoint methods yield comparable adenosine deaminase activity in pleural fluid samples
  41. Congress Abstract
  42. 5th Italian GREAT Network Congress
  43. Congress of Laboratory Medicine and Clinical Chemistry
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 26.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2014-0446/html
Button zum nach oben scrollen